Lantern Pharma heads into its May 14 earnings report with one of the more charged short-side setups in small-cap biotech right now.
Short sellers have built a material position into the print. SI runs at roughly 17.8% of the free float — nearly double where it was a month ago, after a 120% surge in short shares over that period. Days to cover stands at 7.4 on the official FINRA reading, a meaningful number for a stock with a market cap under $25 million. The ORTEX short score is an elevated 80.3, placing LTRN in the top few percent of the universe for short-side pressure. Yet borrow conditions have eased sharply. Cost to borrow has collapsed from above 225% in early April to around 22.6% now — a sign that the acute squeeze environment from six weeks ago has unwound. Availability has tightened to roughly 60% of short interest, sitting in the tighter half of the normal range, but nowhere near the extreme lows of last month.
Options traders are leaning the other way. The put/call ratio has dropped to 0.28 — well below its 20-day average of 0.33 — as call activity dominates. That's a notably bullish tilt from the options market. It matches the price action: LTRN has gained 27% over the past month and 22% in the prior session alone, closing at $2.51 after a sharp single-day rally. The stock's own volatility history shapes what the print can realistically deliver. In March, Lantern's stock rose 22% on the day of its last major release, then extended another 23 percentage points over the following five days. Correlated peer gained 14% on the same day LTRN surged — though most other peers, including and , were flat or negative on the week, highlighting how idiosyncratic LTRN's moves tend to be.
The analytical picture is sparse and dated. Lake Street initiated with a Buy and a $25 target in April 2025 — well above the current $2.51 price — but that gap is too wide to treat as a live benchmark without a more recent update. Fundamentals are pre-revenue; estimated net income is -$17.95 million on zero revenues, with an EPS loss estimate of $1.57. This is a pure pipeline story. Cash runway and clinical progress — not earnings beats — drive the stock.
The contrast between the surging short base and the bullish options tilt makes tonight's print a test of which camp has read the pipeline update correctly.
See the live data behind this article on ORTEX.
Open LTRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
